Conference Paper: Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells

File Download

No File Attached
The HKU Scholars Hub has contact details for these author(s).
- Professor Fan, Sheung Tat
- Professor Wong, John

Supplementary

Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:
- Surgery: Conference papers

Title	Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells
Authors	Fan, ST Yang, ZF Ho, DWY Yu, WC Wong, J
Issue Date	2011
Citation	The 131st Annual Meeting of the American Surgical Association, Boca Raton, FL., 14-16 April 2011. [How to Cite?]
Abstract	OBJECTIVE(S): Recurrence of HCC frequently occurs within the first year after hepatectomy probably due to circulating cancer cells that shed from the primary tumor prior to hepatectomy. Since cancer stem cells (CSCs) are more likely to initiate tumor growth than mature cancer cells, a high level of circulating CSCs may be a hint for HCC recurrence. This study aims to investigate whether circulating CSCs can predict recurrence of HCC after hepatectomy. METHODS: Multi-color flow cytometry was used to detect the number of circulating CSCs (CD45-CD90+CD44+) in the peripheral circulation of 82 patients of HCC one day before hepatectomy. The patients were monitored by CT or MRI for recurrence every three months. RESULTS: Forty-one (50%) patients had recurrence after a median follow-up period of 17.5 months (range 2.7–64.9 months). The patients with recurrence had a higher median level of circulating CSCs than those without recurrence (0.02% vs. 0.01%, p < 0.0001). Circulating CSCs >/=0.01% predicted intrahepatic recurrences (relative risk 3.54, 95% C.I. 1.41–8.88) and extrahepatic recurrences (relative risk 10.15, 95% C.I. 3–34.4). Patients with >0.01% circulating CSCs had a lower two-year disease-free rate (22.7% vs. 64.2%, p < 0.0001) and overall survival rate (58.5% vs. 94.1%, p = 0.0005) than those with </=0.01% circulating CSCs. On multivariate analysis, circulating CSCs >0.01%, tumor stage and tumor size were independent factors affecting the disease-free survival. CONCLUSIONS: Circulating CSCs predicted post-hepatectomy recurrence of HCC with high accuracy. Circulating CSCs may be the target of eradication in the prevention of metastasis of HCC after hepatectomy.
Description	Scientific Session III

DC Field	Value
dc.contributor.author	Fan, ST
dc.contributor.author	Yang, ZF
dc.contributor.author	Ho, DWY
dc.contributor.author	Yu, WC
dc.contributor.author	Wong, J
dc.date.accessioned	2011-06-09T03:47:11Z
dc.date.available	2011-06-09T03:47:11Z
dc.date.issued	2011
dc.description.abstract	OBJECTIVE(S): Recurrence of HCC frequently occurs within the first year after hepatectomy probably due to circulating cancer cells that shed from the primary tumor prior to hepatectomy. Since cancer stem cells (CSCs) are more likely to initiate tumor growth than mature cancer cells, a high level of circulating CSCs may be a hint for HCC recurrence. This study aims to investigate whether circulating CSCs can predict recurrence of HCC after hepatectomy. METHODS: Multi-color flow cytometry was used to detect the number of circulating CSCs (CD45-CD90+CD44+) in the peripheral circulation of 82 patients of HCC one day before hepatectomy. The patients were monitored by CT or MRI for recurrence every three months. RESULTS: Forty-one (50%) patients had recurrence after a median follow-up period of 17.5 months (range 2.7–64.9 months). The patients with recurrence had a higher median level of circulating CSCs than those without recurrence (0.02% vs. 0.01%, p < 0.0001). Circulating CSCs >/=0.01% predicted intrahepatic recurrences (relative risk 3.54, 95% C.I. 1.41–8.88) and extrahepatic recurrences (relative risk 10.15, 95% C.I. 3–34.4). Patients with >0.01% circulating CSCs had a lower two-year disease-free rate (22.7% vs. 64.2%, p < 0.0001) and overall survival rate (58.5% vs. 94.1%, p = 0.0005) than those with </=0.01% circulating CSCs. On multivariate analysis, circulating CSCs >0.01%, tumor stage and tumor size were independent factors affecting the disease-free survival. CONCLUSIONS: Circulating CSCs predicted post-hepatectomy recurrence of HCC with high accuracy. Circulating CSCs may be the target of eradication in the prevention of metastasis of HCC after hepatectomy.
dc.description	Scientific Session III
dc.description.other	The 131st Annual Meeting of the American Surgical Association, Boca Raton, FL., 14-16 April 2011.
dc.identifier.citation	The 131st Annual Meeting of the American Surgical Association, Boca Raton, FL., 14-16 April 2011. [How to Cite?]
dc.identifier.uri	http://hdl.handle.net/10722/133928
dc.language	eng
dc.relation.ispartof	Annual Meeting of the American Surgical Association
dc.title	Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells
dc.type	Conference_Paper

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Fan, ST</contributor.author><contributor.author>Yang, ZF</contributor.author><contributor.author>Ho, DWY</contributor.author><contributor.author>Yu, WC</contributor.author><contributor.author>Wong, J</contributor.author><date.accessioned>2011-06-09T03:47:11Z</date.accessioned><date.available>2011-06-09T03:47:11Z</date.available><date.issued>2011</date.issued><identifier.citation>The 131st Annual Meeting of the American Surgical Association, Boca Raton, FL., 14-16 April 2011.</identifier.citation><identifier.uri>http://hdl.handle.net/10722/133928</identifier.uri><description>Scientific Session III</description><description.abstract>OBJECTIVE(S): Recurrence of HCC frequently occurs within the first year after hepatectomy probably due to circulating cancer cells that shed from the primary tumor prior to hepatectomy. Since cancer stem cells (CSCs) are more likely to initiate tumor growth than mature cancer cells, a high level of circulating CSCs may be a hint for HCC recurrence. This study aims to investigate whether circulating CSCs can predict recurrence of HCC after hepatectomy. METHODS: Multi-color flow cytometry was used to detect the number of circulating CSCs (CD45-CD90+CD44+) in the peripheral circulation of 82 patients of HCC one day before hepatectomy. The patients were monitored by CT or MRI for recurrence every three months. RESULTS: Forty-one (50%) patients had recurrence after a median follow-up period of 17.5 months (range 2.7&#8211;64.9 months). The patients with recurrence had a higher median level of circulating CSCs than those without recurrence (0.02% vs. 0.01%, p &lt; 0.0001). Circulating CSCs &gt;/=0.01% predicted intrahepatic recurrences (relative risk 3.54, 95% C.I. 1.41&#8211;8.88) and extrahepatic recurrences (relative risk 10.15, 95% C.I. 3&#8211;34.4). Patients with &gt;0.01% circulating CSCs had a lower two-year disease-free rate (22.7% vs. 64.2%, p &lt; 0.0001) and overall survival rate (58.5% vs. 94.1%, p = 0.0005) than those with &lt;/=0.01% circulating CSCs. On multivariate analysis, circulating CSCs &gt;0.01%, tumor stage and tumor size were independent factors affecting the disease-free survival. CONCLUSIONS: Circulating CSCs predicted post-hepatectomy recurrence of HCC with high accuracy. Circulating CSCs may be the target of eradication in the prevention of metastasis of HCC after hepatectomy.</description.abstract><language>eng</language><relation.ispartof>Annual Meeting of the American Surgical Association</relation.ispartof><title>Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells</title><type>Conference_Paper</type><description.other>The 131st Annual Meeting of the American Surgical Association, Boca Raton, FL., 14-16 April 2011.</description.other></item>

Conference Paper: Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells

The HKU Scholars Hub has contact details for these author(s).